The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The girl child anthem will portray a celebration of a girl child.
Revenue from operations up 26% to Rs. 768 crores
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Subscribe To Our Newsletter & Stay Updated
